A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNA
<h4>Background</h4> Cancer patients have an increased risk of a severe COVID-19 infection with higher mortality rate. This study aimed to analyze the levels of anti-SARS-CoV-2 S-RBD IgG and NAB among cancer patients who were vaccinated with COVID-19 vaccines, either with BNT162b2, mRNA-1...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977046/?tool=EBI |
| _version_ | 1811160115643940864 |
|---|---|
| author | Andhika Rachman Anggraini Iriani Lugyanti Sukrisman Wulyo Rajabto Nadia Ayu Mulansari Anna Mira Lubis Rahmat Cahyanur Findy Prasetyawati Dimas Priantono Bayu Bijaksana Rumondor Rachelle Betsy Samuel Juanputra |
| author_facet | Andhika Rachman Anggraini Iriani Lugyanti Sukrisman Wulyo Rajabto Nadia Ayu Mulansari Anna Mira Lubis Rahmat Cahyanur Findy Prasetyawati Dimas Priantono Bayu Bijaksana Rumondor Rachelle Betsy Samuel Juanputra |
| author_sort | Andhika Rachman |
| collection | DOAJ |
| description | <h4>Background</h4> Cancer patients have an increased risk of a severe COVID-19 infection with higher mortality rate. This study aimed to analyze the levels of anti-SARS-CoV-2 S-RBD IgG and NAB among cancer patients who were vaccinated with COVID-19 vaccines, either with BNT162b2, mRNA-1273, AZD1222/ChAdOx1nCoV-19, or Coronavac/BBIBP-CorV vaccines. <h4>Method</h4> A cross-sectional study was conducted among subjects with either solid or hematological cancers who had received two doses of either mRNA or non-mRNA vaccines within 6 months. The levels of anti-SARS-CoV-2 S-RBD IgG and NAb were analyzed using the Mindray Immunoassay Analyzer CL-900i. Statistical analysis was conducted using mean comparison and regression analysis. <h4>Result</h4> The mRNA-1273 vaccine had the highest median levels of S-RBD IgG and NAb, followed by BNT162b, ChAdOx1nCoV-19, and BBIBP-CorV/Coronavac. The levels of S-RBD IgG and NAb in subjects vaccinated with mRNA vaccines were significantly higher than those of non-mRNA vaccines when grouped based on their characteristics, including age, type of cancer, chemotherapy regimen, and comorbidity (p<0.05). Furthermore, the S-RBD IgG and NAb levels between the subjects vaccinated with non-mRNA vaccines and the subjects vaccinated with mRNA vaccines were significantly different (p<0.05). However, there was no significant difference between the same types of vaccines. This study demonstrated a very strong correlation between the level of S-RBD IgG and the level of NAb (R = 0.962; p<0.001). The level of anti-SARS-CoV-2 S-RBD IgG was consistently higher compared to the level of NAb. <h4>Conclusions</h4> Generally, mRNA vaccines produced significantly higher anti-SARS-CoV-2 S-RBD IgG and NAb levels than non-mRNA vaccines in cancer subjects. |
| first_indexed | 2024-04-10T05:53:15Z |
| format | Article |
| id | doaj.art-c333041d1a3d497294f7a6c77f4f02c3 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-10T05:53:15Z |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-c333041d1a3d497294f7a6c77f4f02c32023-03-04T05:31:10ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01183A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNAAndhika RachmanAnggraini IrianiLugyanti SukrismanWulyo RajabtoNadia Ayu MulansariAnna Mira LubisRahmat CahyanurFindy PrasetyawatiDimas PriantonoBayu Bijaksana RumondorRachelle BetsySamuel Juanputra<h4>Background</h4> Cancer patients have an increased risk of a severe COVID-19 infection with higher mortality rate. This study aimed to analyze the levels of anti-SARS-CoV-2 S-RBD IgG and NAB among cancer patients who were vaccinated with COVID-19 vaccines, either with BNT162b2, mRNA-1273, AZD1222/ChAdOx1nCoV-19, or Coronavac/BBIBP-CorV vaccines. <h4>Method</h4> A cross-sectional study was conducted among subjects with either solid or hematological cancers who had received two doses of either mRNA or non-mRNA vaccines within 6 months. The levels of anti-SARS-CoV-2 S-RBD IgG and NAb were analyzed using the Mindray Immunoassay Analyzer CL-900i. Statistical analysis was conducted using mean comparison and regression analysis. <h4>Result</h4> The mRNA-1273 vaccine had the highest median levels of S-RBD IgG and NAb, followed by BNT162b, ChAdOx1nCoV-19, and BBIBP-CorV/Coronavac. The levels of S-RBD IgG and NAb in subjects vaccinated with mRNA vaccines were significantly higher than those of non-mRNA vaccines when grouped based on their characteristics, including age, type of cancer, chemotherapy regimen, and comorbidity (p<0.05). Furthermore, the S-RBD IgG and NAb levels between the subjects vaccinated with non-mRNA vaccines and the subjects vaccinated with mRNA vaccines were significantly different (p<0.05). However, there was no significant difference between the same types of vaccines. This study demonstrated a very strong correlation between the level of S-RBD IgG and the level of NAb (R = 0.962; p<0.001). The level of anti-SARS-CoV-2 S-RBD IgG was consistently higher compared to the level of NAb. <h4>Conclusions</h4> Generally, mRNA vaccines produced significantly higher anti-SARS-CoV-2 S-RBD IgG and NAb levels than non-mRNA vaccines in cancer subjects.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977046/?tool=EBI |
| spellingShingle | Andhika Rachman Anggraini Iriani Lugyanti Sukrisman Wulyo Rajabto Nadia Ayu Mulansari Anna Mira Lubis Rahmat Cahyanur Findy Prasetyawati Dimas Priantono Bayu Bijaksana Rumondor Rachelle Betsy Samuel Juanputra A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNA PLoS ONE |
| title | A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNA |
| title_full | A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNA |
| title_fullStr | A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNA |
| title_full_unstemmed | A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNA |
| title_short | A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNA |
| title_sort | comparative study of the covid 19 vaccine efficacy among cancer patients mrna versus non mrna |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977046/?tool=EBI |
| work_keys_str_mv | AT andhikarachman acomparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT anggrainiiriani acomparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT lugyantisukrisman acomparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT wulyorajabto acomparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT nadiaayumulansari acomparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT annamiralubis acomparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT rahmatcahyanur acomparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT findyprasetyawati acomparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT dimaspriantono acomparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT bayubijaksanarumondor acomparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT rachellebetsy acomparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT samueljuanputra acomparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT andhikarachman comparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT anggrainiiriani comparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT lugyantisukrisman comparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT wulyorajabto comparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT nadiaayumulansari comparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT annamiralubis comparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT rahmatcahyanur comparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT findyprasetyawati comparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT dimaspriantono comparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT bayubijaksanarumondor comparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT rachellebetsy comparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna AT samueljuanputra comparativestudyofthecovid19vaccineefficacyamongcancerpatientsmrnaversusnonmrna |